ReviewRelapsing polychondritis
Introduction
Relapsing polychondritis (RP) is a rare connective tissue disease in which recurrent bouts of inflammation, followed in some cases by degeneration and deformation, involve the cartilage of the ears, nose, larynx, and tracheobronchial tree [1], [2], [3], [4], [5], [6]. RP is a systemic disease, as shown by the frequent presence of arthritis, ocular inflammation, audiovestibular involvement, skin lesions, heart valve incompetence, and vasculitis. This article reviews the current knowledge about RP with special emphasis on the most recent data.
Section snippets
Method
We searched Medline using the following indexing terms: relapsing polychondritis, chondritis, cartilage, associated autoimmune disease, arthritis, respiratory tract, imaging, computed tomography, MRI, PET scan, pathogenesis, and treatment. Reference lists of retrieved publications were searched manually for additional articles.
Epidemiology
RP chiefly affects middle-aged adults, with a slight female predominance. Cases have been reported in the very young and very elderly [7]. All ethnic groups are affected. In the US, the estimated annual incidence of RP is 3.5/106 population [3] and the prevalence among Department of Defense beneficiaries is 4.5/106 [6].
Presentation
The presenting manifestations are highly variable. Joint symptoms often inaugurate the disease, and chondritis is absent initially in nearly half the cases, resulting in diagnostic delays of several months or years. The development of chondritis provides the correct diagnosis in patients evaluated initially for joint, ocular, cutaneous, or audiovestibular abnormalities that were either misinterpreted or unexplained. In patients with chondritis at presentation, the pinna is the most common site
Investigations
Laboratory evidence of inflammation is the rule during disease flares but when absent does not rule out RP. Known antibodies against certain cartilage components (collagen type II and matrilin-1) are neither sensitive nor specific and therefore cannot be used to diagnose RP. Blood cell counts may indicate myelodysplastic syndrome, usually refractory anemia with or without excess of blasts, which is seen in 5% to 10% of cases, chiefly early in the disease in males older than 60 years of age [2],
Diagnosis
The diagnosis of RP rests on clinical grounds and is frequently delayed.
Histological studies are not specific [4] and are rarely performed in everyday practice. However, histology may be helpful in early or atypical forms of RP. Examination of cartilage biopsies shows a perichondral infiltrate of lymphocytes and plasma cells with loss of basophilic staining of the cartilage matrix indicating loss of proteoglycans. The cartilage is gradually replaced by fibrous tissue. These abnormalities
Pathophysiology
An accumulating body of evidence points to an autoimmune response against certain cartilage antigens, which have not yet been identified, with subsequent cartilage matrix destruction by proteases including proteases released by chondrocytes undergoing apoptosis [4], [16], [17], [18].
Several lines of evidence support a pathogenic role for the humoral and cellular immune systems [4]:
- 1.
about 30% of patients with RP also have another autoimmune disease (Table S1);
- 2.
the damaged cartilage is infiltrated
Disease course
In most patients, RP is a chronic progressive disease characterized by a succession of flare-ups of variable frequency and severity. A burden of pain and functional impairment develops over time and may be compounded by iatrogenic complications. Remissions of variable duration may occur. Pregnancy has no effect on the activity of RP, and there are no neonatal manifestations [4], [38].
The Relapsing Polychondritis Disease Activity Index (RPDAI) is a recently developed preliminary score for
Prognosis
Improvements in the outcomes of patients with RP have been achieved in recent years, probably because better knowledge of the disease allows the diagnosis of mild forms and the development of better treatment strategies. Survival rates have increased from 70% after 5 years [1], [2], to 94% after 8 years [4] and even 91% after 10 years in a recent large single-center study [40]. RP-related causes of death include specific organ involvements (blood vessels and airways); concomitant myelodysplastic
Treatment
No controlled trials are available on which to base treatment decisions in RP. The treatment regimen is tailored empirically to each individual patient, based on clinical activity and severity [6], [8].
Antiinflammatory drugs, colchicine, or dapsone can be tried in mild forms, but their effectiveness is limited [2], [4]. Low-dose glucocorticoid therapy is often required.
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
References (47)
- et al.
Relapsing polychondritis: an autoimmune disease with many faces
Autoimmun Rev
(2010) - et al.
Relapsing polychondritis in the Department of Defense population and review of the literature
Semin Arthritis Rheum
(2012) - et al.
Pediatric-onset relapsing polychondritis: case series and systematic review
J Pediatr
(2010) - et al.
Relapsing polychondritis and airway involvement
Chest
(2009) - et al.
Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behçet's disease
Am J Med
(1985) - et al.
Cardiovascular involvement in relapsing polychondritis
Semin Arthritis Rheum
(1997) - et al.
Central nervous system involvement in relapsing polychondritis
Joint Bone Spine
(2010) - et al.
Meningoencephalitis or meningitis in relapsing polychondritis: four case reports and a literature review
J Clin Neurosci
(2011) - et al.
Pathogenesis of relapsing polychondritis: a 2013 update
Autoimmun Rev
(2014) - et al.
Cartilage as a target of autoimmunity: a thin layer
Autoimmun Rev
(2013)
Amelioration of relapsing polychondritis in a child treated with oral collagen
Am J Med Sci
The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis
Autoimmun Rev
Biologics in relapsing polychondritis: a literature review
Semin Arthritis Rheum
Surgical treatment of the cardiac manifestations of relapsing polychondritis: overview of 33 patients identified through literature review and the Mayo Clinic records
Mayo Clin Proc
Relapsing polychondritis: prospective study of 23 patients and a review of the literature
Medicine (Baltimore)
Relapsing polychondritis. Survival and predictive role of early disease manifestations
Ann Intern Med
Relapsing polychondritis
Relapsing polychondritis
Ann Intern Med
Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center
Medicine (Baltimore)
Relapsing polychondritis: prevalence of expiratory CT airway abnormalities
Radiology
Fluorodeoxyglucose PET in relapsing polychondritis
N Engl J Med
Cartilage destruction is partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in relapsing polychondritis
J Rheumatol
Antibodies to type II collagen in relapsing polychondritis
N Engl J Med
Cited by (59)
Tracheobronchial involvement of relapsing polychondritis
2019, Autoimmunity ReviewsCitation Excerpt :In addition, costosternal chondritis can also affect breathing, occasionally even resulting in complete cartilaginous destruction. Costosternal chondritis is present in 35% of patients [14]. RP can lead to sudden death (due to laryngeal or tracheal spasm) or acute edema during an inflammatory attack.
Tracheobronchial involvement of relapsing polychondritis
2018, Revue du Rhumatisme MonographiesAutoimmunity and Autoinflammation: Relapsing Polychondritis and VEXAS Syndrome Challenge
2024, International Journal of Molecular SciencesRED EARS, RED EYES AND HEARING LOSS: A DIAGNOSTIC DILEMMA
2023, Journal of Health and Translational MedicineRelapsing polychondritis with ANCA-associated vasculitis: is it a coincidence or an overlapping condition?
2023, Clinical and Experimental Rheumatology